LDS/Medical Tests/Cyclin-D1 (BCL1) Expression, Immunohistochemistry, Tissue

Cyclin-D1 (BCL1) Expression, Immunohistochemistry, Tissue

Cyclin D1 is a pivotal regulator of the cell cycle, particularly in the transition from the G1 to S phase. In normal cells, its expression is tightly controlled; however, in various cancers, this regulation is often disrupted. Amplification of the CCDN1 gene, which encodes Cyclin D1, has been observed in several tumor types and is considered a negative prognostic marker.

Beyond its nuclear functions, Cyclin D1 has been implicated in tumor progression through its presence in the cytoplasm. Its localization to the cytoplasmic membrane is associated with enhanced tumor invasion and metastasis. Additionally, Cyclin D1 influences the tumor microenvironment by regulating the expression of specific microRNAs and modulating interactions between tumor cells, stromal components, and the immune system.

The overexpression of Cyclin D1 has been implicated in various lymphoma subtypes, including mantle cell lymphoma (MCL), follicular lymphoma, and B-cell chronic lymphocytic leukemia (B-CLL). In lymphoma, Cyclin D1 overexpression is commonly observed and is often associated with the t(11;14)(q13;q32) translocation. It is more common in mantle cell lymphoma (MCL) with a 65% prevalence. However, some lymphoma occurs in the absence of this translocation as well. B-cell lymphoma are more common and account for 80% - 90% of all lymphomas.

Targeting Cyclin D1 pathways offers promising therapeutic avenues. Inhibitors that specifically target Cyclin D1 or its downstream signaling pathways could impede tumor cell proliferation and improve patient outcomes. Additionally, measuring Cyclin D1 expression levels may aid in diagnosing certain lymphoma subtypes and predicting disease progression. Understanding the multifaceted role of Cyclin D1 in lymphoma pathogenesis is crucial for developing effective treatment strategies and advancing personalized medicine approaches in oncology.

  • As an aid in the diagnosis of lymphoma
  • Aid in the differential diagnosis of mantle cell lymphoma
  • As an aid in the classification of low-grade B-cell lymphomas

Positive Nuclear Staining:

Strong nuclear staining in ≥10% of tumor cells is considered positive and indicates Cyclin D1 overexpression, commonly seen in mantle cell lymphoma.

Staining can also be observed in rare cases of diffuse large B-cell lymphoma (DLBCL), B-cell chronic lymphocytic leukemia (B-CLL), and multiple myeloma. This supports diagnosis but must be interpreted alongside morphology, flow cytometry, and cytogenetic studies (e.g., t(11;14)(q13;q32) translocation).

Negative Staining:

Absence of nuclear staining or staining <10% of tumor cells is considered negative and indicates that Cyclin D1 is not overexpressed; helps exclude MCL in the differential diagnosis.

Negative: <10% nuclear staining in tumor cells Positive: ≥10% nuclear staining in tumor cells

Immunohistochemistry (IHC).

Formalin-fixed, paraffin-embedded (FFPE) tissue.

Stability

FFPE is stable at room temperature for longer time.

Lymph node biopsy, leukemia/lymphoma immunophenotyping by flow cytometry, CBC, comprehensive metabolic panel, uric acid, beta-2 macroglobulin.
1 to 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login